Supplements can be a helpful part of any IBS management strategy. However, there are a wide variety of digestive health supplements available, and knowing which ones are evidence-based can save you time and money.
Click to navigate the video
Supplements can be a helpful part of any IBS management strategy. However, there are a wide variety of digestive health supplements available, and knowing which ones are evidence-based can save you time and money.
Soluble fiber has strong evidence supporting its use for IBS symptom relief. For example, a 2014 meta-analysis showed soluble fiber was effective in reducing symptoms in patients with IBS. This effect was not seen with insoluble fiber supplementation.
Soluble fiber dissolves in water and works to normalize stool consistency. Meta-analyses show that soluble fiber, especially psyllium husk, improves global IBS symptoms, abdominal pain, and stool consistency. Additionally, soluble fiber helps support the gut microbiota. When soluble fiber is fermented, it produces short-chain fatty acids—which are compounds that support overall gut health.
Soluble fiber can be found in foods such as oats, barley, legumes, and chia seeds. Many patients find it helpful to take a soluble fiber supplement to support their IBS symptoms in addition to adding soluble fiber into their diet. The soluble fiber supplement with the strongest research among patients with IBS is psyllium.
When increasing fiber (either through the diet or supplementation), it is important to start with small amounts and increase gradually to minimize any new symptoms such as gas and bloating. If you do experience these symptoms, they are usually temporary as the gut gets used to the additional fiber.
Peppermint oil is another commonly used supplement for IBS symptoms. Studies have shown peppermint oil can improve IBS symptoms, particularly abdominal pain. The most recent American College of Gastroenterology IBS management guidelines suggest the use of peppermint oil as a treatment option to provide relief of IBS symptoms.
Peppermint works by relaxing smooth muscle in the gut and may have some anti-inflammatory effects in the gut. Peppermint oil can come in many forms. The formulation with the strongest evidence is an enteric-coated microsphere preparation called IBgard that is designed to be delivered in the small intestine, where it is believed to work. In a one-month clinical trial, this peppermint oil product has been shown to improve multiple GI symptoms of IBS.
Commercial insurance typically does not cover peppermint oil products, and usually the cost of the product is out of pocket. Additionally, some patients report peppermint can exacerbate GERD (acid reflux) symptoms, although the enteric-coated forms are intended to reduce this risk.
Digestive enzymes are proteins that help break down food for absorption. Our digestive system produces these enzymes to break down essential nutrients like carbohydrates, proteins, and fats.
Digestive enzymes have become widely popular for treating a wide range of digestive issues. Supplementing with a digestive enzyme can help alleviate symptoms in individuals with certain gastrointestinal conditions, including IBS. However, selecting the right type of enzyme for the specific condition is imperative.
For IBS patients who are sensitive to FODMAPs, digestive enzymes targeted at breaking down FODMAPs can be helpful. While these enzymes are not a cure, they can offer more flexibility and reduce stress around eating.
Examples of specific digestive enzymes:
| Enzyme | FODMAP | Examples of foods |
|---|---|---|
| Alpha galactosidase | Galacto-oligosaccharides (GOS) | Found in lentils, beans and nuts |
| Lactase | Lactose | Found in milk, cheese, and ice cream |
| Inulase or fructan hydrolase | Fructans | Found in onions, garlic and wheat |
| Xylose isomerase | Fructose | Found in fruit, honey, agave and other sweeteners |
| Invertase or sucrase | Sucrose | Found in fruit, table sugar, honey and maple syrup |
Fodzyme and Intoleran are two common digestive enzyme brands used by GI clinicians. Selecting a digestive enzyme is dependent on individual FODMAP intolerances and should be guided by a healthcare professional.
Probiotic supplements are widely popular and are among the most commonly used supplements for IBS. Despite their popularity, there is limited high-quality clinical evidence supporting the widespread use of probiotics in patients with IBS. In fact, based on the available research, both the American Gastroenterological Association (AGA) and the American College of Gastroenterology recommend against the routine use of probiotics for IBS in recent management guidelines.
In clinical practice, probiotic use for IBS is highly variable based on individual patient and provider preferences. Most gastroenterology providers view probiotic supplements as one of many potential treatment options for IBS. Some patients respond well to probiotic supplements, while others experience little to no benefit from probiotic supplements.
Below are some important considerations when considering a trial of probiotic supplements for IBS symptoms:
The table below summarizes commercially available probiotic strains with evidence to support potential benefit for IBS symptoms.
| Probiotic strain | Available brands | Symptom benefit | Population studied | Key clinical trial or meta-analysis |
|---|---|---|---|---|
| Escherichia coli DSM 17252 | Symbioflor-2 (Europe) | Global symptoms, abdominal pain | General IBS population | Enck et al., Z Gastroenterol 2009; Goodoory et al., Gastroenterology 2023. |
| Bifidobacterium longum subsp. longum 35624 (previously Bifidobacterium infantis 35624) | Align (US); Alflorex (Europe) | Global symptoms, abdominal pain, bloating, bowel dysfunction (weak) | General IBS population | Whorwell et al., Am J Gastroenterol 2006; Goodoory et al., Gastroenterology 2023; Maslennikov et al., J Clin Med 2026. |
| Bifidobacterium bifidum MIMBb75 (viable and heat-inactivated/postbiotic forms) | Kijimea IBS (Europe) | Global symptoms, abdominal pain, bloating | General IBS population | Guglielmetti et al., Aliment Pharmacol Ther 2011; Andresen et al., Lancet Gastroenterol Hepatol 2020; Goodoory et al., Gastroenterology 2023. |
| Lactiplantibacillus plantarum 299v (previously Lactobacillus plantarum 299v) | Sanprobi IBS (Europe); Jarrow Formulas Ideal Bowel Support (US) | Abdominal pain scores and global symptoms; no significant effect on pain persistence; bloating (weak evidence) | General IBS population | Ducrotté et al., World J Gastroenterol 2012; Goodoory et al., Gastroenterology 2023; Maslennikov et al., J Clin Med 2026. |
| Bacillus coagulans Unique IS2 (MTCC 5260) | MIOME IB-ONE (US) | Abdominal pain, bowel movements, bloating, global symptoms | General IBS population | Madempudi et al., Sci Rep 2019; Maslennikov et al., J Clin Med 2026. |
| Lacticaseibacillus rhamnosus GG (previously Lactobacillus rhamnosus GG) | Culturelle (US) | Global symptoms, abdominal pain | General IBS population (strongest evidence in pediatric population, limited adult evidence) | Francavilla et al., Pediatrics 2010; Horvath et al., Aliment Pharmacol Ther 2011; Preidis et al., Gastroenterology 2020; Maslennikov et al., J Clin Med 2026. |
The table below reviews the evidence behind other supplements that patients may consider using for their IBS symptoms. Evidence for these supplements varies, with many of them having little to no evidence. Supplements should only be used under the direction of a healthcare professional.
| Supplement | Proposed target symptoms | Summary of evidence and safety considerations | Key clinical trial(s) or meta-analyses |
|---|---|---|---|
| Enterosgel | IBS-D | Intestinal adsorbent available as oral suspension in the UK and Europe (not FDA approved in the US). Moderate evidence for improvement in abdominal pain and diarrhea over placebo in IBS-D patients. Considered a medical device. Needs separate dosing from other medications. | Yiannakou et al., Gut 2022. |
| Iberogast (STW 5) | Abdominal pain in IBS patients (independent of subtype) and patients with IBS/dyspepsia overlap | Combination of nine herbal extracts (bitter candytuft, chamomile, peppermint, caraway, liquorice, lemon balm, celandine, angelica, milk thistle). Moderate evidence for improvement in abdominal pain symptoms over placebo for IBS patients, also used in dyspepsia. Rare cases of liver injury, has regulatory label warnings to avoid in active liver disease. | Madisch et al., Aliment Pharmacol Ther 2004; Aguilar et al., Neurogastroenterol Motil 2024. |
| Melatonin | Global IBS symptoms, particularly abdominal pain; sleep disturbances | Hormone with proposed gut-brain and visceral-analgesic effects in addition to sleep aid. Moderate evidence for improvement in overall IBS severity and pain severity over placebo, with benefit independent of sleep improvement. Typical dose 3 mg at bedtime. May cause daytime drowsiness, caution when using other sedative medications. Potential to interact with other medications. | Song et al., Gut 2005; Chen et al., J Formos Med Assoc 2023. |
| L-glutamine | Post-infectious IBS-D | Amino acid that restores intestinal barrier integrity. Single clinical trial with a large effect in post-infectious IBS-D patients with increased intestinal permeability; symptom improvement correlated with normalization of permeability. Dose 5g three times daily. Larger confirmatory trials still needed. Caution in hepatic encephalopathy/cirrhosis. | Zhou et al., Gut 2019. |
| Magnesium (oxide / citrate) | IBS-C (extrapolated from chronic constipation studies) | Osmotic laxative that draws water into the intestinal lumen. Moderate evidence for chronic idiopathic constipation rather than IBS-C specifically. Avoid in significant renal impairment. Can reduce absorption of some medications. | Morishita et al., Am J Gastroenterol 2021; AGA-ACG Chronic Idiopathic Constipation Guideline 2023. |
| Curcumin (principal bioactive compound in turmeric) | Global IBS symptoms | Polyphenol with anti-inflammatory, antioxidant, and microbiome-modulating properties. Evidence is limited and variable with some showing benefit and others without significant benefit in IBS. High doses may cause liver injury. Interaction with other medications with potential for increased bleeding risk with antiplatelet and anticoagulant medications. | Bundy et al., J Altern Complement Med 2004; Ng et al., J Clin Med 2018. |
| Vitamin D | Global symptoms in deficient patients | Fat-soluble vitamin with immunomodulatory, anti-inflammatory and serotonergic-regulatory effects; low vitamin D status is common in IBS. Limited inconsistent evidence. Benefit, where observed, in correcting baseline deficiency. No evidence to support supplementation in patients who are not deficient. | Abbasnezhad et al., Neurogastroenterol Motil 2016; Cara et al., Crit Rev Food Sci Nutr 2024. |
| Aloe vera | IBS-D; global symptoms | Succulent extract with immunomodulatory and possible prebiotic (glucomannan) properties. Limited/mixed evidence. AGA guidance explicitly discourages aloe vera use in IBS. Latex/whole-leaf preparations have laxative effects and can cause cramping and electrolyte (potassium) loss. | Ahluwalia et al., Ther Adv Gastroenterol 2021; Ahluwalia et al., Neurogastroenterol Motil 2020; Chey et al., Gastroenterology 2022. |
| PEA (palmitoylethanolamide) | Abdominal pain | Endogenous fatty-acid amide with anti-inflammatory and analgesic actions. Emerging evidence from a single small trial of PEA effective in reducing abdominal pain severity but not other IBS symptoms. Mechanism not fully established. Very limited safety and drug-interaction data. | Cremon et al., Aliment Pharmacol Ther 2017. |
| Bovine colostrum | IBS-D | First-milk secretion rich in immunoglobulins (predominantly IgG), lactoferrin, and growth factors, proposed to improve intestinal permeability and barrier integrity. Very limited evidence; a small pilot study of serum-derived bovine immunoglobulin improved symptoms in IBS-D over 6 weeks, and systematic reviews support benefit in diarrhea more broadly, but other IBS-specific trials are lacking. Product origin, standardization and Ig content vary widely. Avoid in mild protein allergy and use in caution with lactose intolerance. | Gibson et al., Gastroenterology 2015; Hajihashemi et al., Syst Rev 2024. |
| Berberine | IBS-D | Plant alkaloid with reported antimicrobial, antisecretory, antimotility, and pain-blocking properties. Limited evidence from a single clinical trial showing reduced diarrhea frequency, abdominal pain frequency, and defecation urgency versus placebo, with symptom rebound after discontinuation. Risk of significant drug interactions and should be avoided in pregnancy and children. | Chen et al., Phytother Res 2015. |
| CBD (cannabidiol) | Abdominal pain | Non-psychotropic cannabinoid proposed to modulate visceral pain. Single small trial for IBS showed no benefit for pain or quality of life. Over-the-counter products have unreliable content/purity. Common GI adverse effects, risk of liver injury and interactions with other medications. | Brierley et al., Nat Rev Gastroenterol Hepatol 2023. |
| Digestive bitters | Global symptoms | Bitter herbal blends proposed to stimulate salivary/gastric secretion and motility via bitter taste-receptor activation. No IBS-specific data. | No IBS clinical trials. |
| Slippery elm | Global symptoms; IBS-C (proposed fiber effect) | Ulmus rubra inner-bark mucilage often included in multi-ingredient bowel formulas. No IBS-specific studies for slippery elm on its own. May cause bloating, gas and impair absorption of oral medication due to mucilaginous fiber properties. | No IBS clinical trials for slippery elm monotherapy. |
| Sea moss | Global symptoms (proposed prebiotic/demulcent) | Marketed as a functional food for gut and general health, with proposed prebiotic and mucilaginous effects. No IBS clinical trials. Iodine rich—excessive intake may cause thyroid dysfunction. Commercial products show substantial variability in heavy metal and microbial contamination. Quality is poorly regulated. | No IBS clinical trials. |
| Ashwagandha | Stress-related global symptoms | Adaptogenic root extract with anxiolytic and HPA-axis-modulating effects, of theoretical interest for stress-associated gut-brain symptoms. No IBS-specific clinical trials. Risk of liver injury and thyroid toxicity. Risk of sedation. | No IBS clinical trials. |
| Apple cider vinegar | Global symptoms; reflux/dyspepsia (proposed) | Commonly used remedy popularly used for GI and metabolic complaints. No IBS clinical trials. Highly acidic with risk of dental and esophageal injury. Potential interaction with medications. | No IBS clinical trials. |